Pharma giant Eli Lilly has made yet another major announcement for its weight loss drug tirzepatide, which has demonstrated efficacy in being able to help pre diabetic patients reduce their risk of contracting diabetes. In a release shared earlier today, the drug maker announced that different tirzepatide doses at a weekly interval ended up reducing the risk of diabetes among pre diabetic patients by as much as 94%. As an added bonus, users dosed with the highest dosage also managed to cut their weight by a quarter. These results came from a three year study that evaluated the drug’s effectiveness […]
Read full article at https://wccftech.com/eli-lillys-weight-loss-drug-cuts-diabetes-risk-by-88-from-earlier-94-after-stopping-treatment/
